WASHINGTON (dpa-AFX) - Clinical-stage vaccine company Novavax, Inc., (NVAX) reported a net loss of $31.5 million or $0.13 per share for the fourth quarter, compared to a net loss of $14.1 million or $0.07 per share for the year-ago quarter.
Revenue for the fourth quarter fell 23% to $6.7 million from $8.7 million a year earlier.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.08 per share on revenue of $9.60 million for the fourth quarter.
Copyright RTT News/dpa-AFX
© 2015 AFX News
